KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema-Reference-Cited by-同舟云学术

KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema

Published:2024-04 Issue: Volume:260 Page:70-83
ISSN:0002-9394
Container-title:American Journal of Ophthalmology
language:en
Short-container-title:American Journal of Ophthalmology

Author:

Wykoff Charles C.^ORCID,Garweg Justus G.^ORCID,Regillo Carl,Souied Eric,Wolf Sebastian^ORCID,Dhoot Dilsher S.,Agostini Hansjuergen T.,Chang Andrew,Laude Augustinus,Wachtlin Joachim,Kovacic Lidija,Wang Lixin,Wang Ying,Bouillaud Emmanuel,Brown David M.

Publisher

Elsevier BV

Subject

Ophthalmology

Reference29 articles.

1. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis;Teo;Ophthalmology,2021

2. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naive patients with diabetic macular edema: results from the real-world global LUMINOUS study;Mitchell;PLoS One,2020

3. A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS);Stefanickova;Acta Ophthalmol,2018

4. Intravitreal ranibizumab therapy for diabetic macular edema in routine practice: two-year real-life data from a non-interventional, multicenter study in Germany;Ziemssen;Diabetes Ther,2018

5. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes;Ciulla;Br J Ophthalmol,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reproducibility of Portable OCT and Comparison with Conventional OCT;Diagnostics;2024-06-21

2. Diabetische Retinopathie und diabetisches Makulaödem;Die Diabetologie;2024-04-29

3. Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema;Journal of Clinical Medicine;2024-03-21

4. Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab;Journal of Clinical Medicine;2024-03-07

5. Real-World Experience With Brolucizumab 6 mg for Diabetic Macular Edema;Cureus;2024-01-12